Skip to Main Content

Opinions+

Perspectives on issues affecting biopharma and health care.

Latest

Opinions+ Ashu Singhal and Sajith Wickramasekara

STAT Plus: Could billions of dollars in AI funding lead to the same number of new drugs?

Opinions+ Hope Meely

STAT Plus: Unmasking the ‘centricity’ illusion in clinical trials

Opinions+ Lee A. Fleisher and Matthew A. Fleisher

STAT Plus: Use evidence to support early coverage of gene therapy after accelerated approval

Opinions+ Wendy Cheng

STAT Plus: How AI can help satisfy FDA’s drug, device diversity requirements

Opinions+ Kyle H. Sheetz and Robert M. Wachter

STAT Plus: Medical devices makers are trying to take a page from Uber’s playbook

First Opinion Amit Etkin

STAT Plus: It’s time to rethink everything about our approach to psychiatric drug development

First Opinion Juliana M. Reed

STAT Plus: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

First Opinion Dan Troy

STAT Plus: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

All Coverage

Opinions+ John Whyte

STAT Plus: Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit

First Opinion Shirley Leung

STAT Plus: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker

advertisement

First Opinion Peter Shen

STAT Plus: Health care AI requires a new Hippocratic oath

Opinions+ Paul Jones

STAT Plus: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint

First Opinion Tommy Bramley, Herbert Altmann, and Casper Paardekooper

STAT Plus: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients

First Opinion Brian Finrow

STAT Plus: Preventive drugs may be the best solution to the antibiotic resistance crisis

First Opinion Vijay Ramakrishnan

STAT Plus: How payer-participating trials could help transform clinical research on FDA-approved drugs

First Opinion Leah Christl

STAT Plus: The problem with potential changes to the biosimilar regulatory framework

First Opinion Paul Hudson

STAT Plus: Sanofi CEO Paul Hudson: The right way to bring AI into pharma

First Opinion Anna Sparrow

STAT Plus: One way to create resilient drug supply chains: incentivize predictive models

First Opinion Owen Tripp

STAT Plus: How I’m helping companies think through whether they should cover GLP-1s like Ozempic for employees

First Opinion Gloria Coronado and Leslie Bienen

STAT Plus: An overlooked way to make participants in clinical trials look more like America

Opinions+ Ben Green

STAT Plus: At-home clinical trials are the future

Opinions+ Peter G. Lurie and Beth Ellikidis

STAT Plus: Where are the guidelines for the production of animals with intentional genomic alterations?

Opinions+ Dave Greenwald

STAT Plus: 3 keys to successful biopharma-academia drug development collaborations

Opinions+ Irfan Khan

STAT Plus: Developing new drugs starts with building the next generation of clinical investigators

Opinions+ Christine Swisher and Gabriel Seidman

STAT Plus: 4 concrete steps to realize the AI Bill of Rights for clinical decision support software

Opinions+ Patricia Hurter

STAT Plus: Continuous manufacturing can help pharma companies save time, money, and more

Opinions+ Thomas Newcomer

STAT Plus: Removing barriers to biosimilar adoption in the United States

Opinions+ Ashley Beecy, Steve Miff, and Karandeep Singh

STAT Plus: HHS’s proposed rule prohibiting discrimination via algorithm needs strengthening

Opinions+ Meg Richards

STAT Plus: The need for regulatory grade evidence: Are you in the stadium or the sandbox?